Bilimoria Karl Y, Palis Bryan, Stewart Andrew K, Bentrem David J, Freel Andrew C, Sigurdson Elin R, Talamonti Mark S, Ko Clifford Y
Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Dis Colon Rectum. 2008 Feb;51(2):154-61. doi: 10.1007/s10350-007-9114-2. Epub 2008 Jan 3.
Adequate lymph node evaluation is important to stage colon cancers and make adjuvant treatment decisions. Studies have demonstrated improved survival when >or= 12 nodes are examined. Our objective was to assess differences in the adequacy of nodal evaluation for right vs. left colon cancers.
From the National Cancer Data Base (1998-2004), 142,009 N0M0 colon cancer patients were identified. Logistic regression was used to evaluate the number of nodes examined for right vs. left colectomies. Multivariable modeling was used to determine the impact of examining >or= 12 nodes on survival.
Of 142,009 patients, 79,444 (56 percent) had right colectomies, and 62,565 (44 percent) patients had left colectomies. More nodes were examined during right colectomies than left (median 12 vs. 8, P<0.0001). When adjusted for patient, tumor, and hospital factors, patients undergoing left colectomy were less likely to have >or= 12 nodes identified (P<0.0001). Patients were more likely to have >or= 12 nodes identified for right and left colon cancers at high-volume hospitals. Survival was better with examination of >or= 12 nodes for right and left colon cancers (P < 0.0001).
Evaluating >or= 12 nodes for right and left colon cancers is a feasible, clinically relevant, and modifiable factor that will likely improve patient outcomes.
充分的淋巴结评估对于结肠癌分期及做出辅助治疗决策至关重要。研究表明,检查≥12个淋巴结时患者生存率有所提高。我们的目的是评估右半结肠癌与左半结肠癌淋巴结评估充分性的差异。
从国家癌症数据库(1998 - 2004年)中,识别出142,009例N0M0结肠癌患者。采用逻辑回归评估右半结肠切除术与左半结肠切除术检查的淋巴结数量。使用多变量模型确定检查≥12个淋巴结对生存率的影响。
在142,009例患者中,79,444例(56%)接受了右半结肠切除术,62,565例(44%)接受了左半结肠切除术。右半结肠切除术中检查的淋巴结比左半结肠切除术更多(中位数分别为12个和8个,P<0.0001)。在对患者、肿瘤和医院因素进行调整后,接受左半结肠切除术的患者识别出≥12个淋巴结的可能性较小(P<0.0001)。在高容量医院,右半结肠癌和左半结肠癌患者识别出≥12个淋巴结的可能性更大。检查≥12个淋巴结时,右半结肠癌和左半结肠癌患者的生存率更高(P<0.0001)。
对右半结肠癌和左半结肠癌评估≥12个淋巴结是一个可行、具有临床相关性且可改变的因素,可能会改善患者预后。